MONTEREY, Calif., Sept. 24 /PRNewswire/ -- Today, the rights to Verus Pharmaceuticals' pediatric asthma development programs that utilize PARI's eFlow electronic nebulizer for aerosol delivery were acquired by AstraZeneca. Following Gilead Sciences' acquisition of Corus Pharma in August 2006, this is the second major pharmaceutical acquisition where a licensed eFlow is featured prominently in the development pipeline.
Included in the AstraZeneca acquisition are the North American rights to a Captisol(R) enabled budesonide solution (controller medication), a proprietary short-acting beta-agonist solution (rescue medication), a customized version of eFlow(R) (novel aerosol delivery device) for use with both products, and other intellectual property and related assets from Verus.
This is the second acquisition by a large pharmaceutical company where purchases have included the licensing of PARI's eFlow in the development program. In August 2006, Gilead Sciences acquired Corus Pharma for $365 million. In December 2006, Gilead Sciences released positive preliminary results of their Phase III trial on AIR-CF2, a potential treatment for cystic fibrosis patients that have pulmonary Pseudomonas aeruginosa. These positive preliminary results were the first Phase III clinical trial results highlighting the optimization of drug to device and device to drug with PARI's eFlow, an advanced electronic nebulizer.
eFlow uses a vibrating, perforated membrane that enables extremely
efficient aerosolization of liquid medications. Compared to other nebulizer
systems, eFlow can produce aerosols with a very high density of active
drug, a precisely defined droplet size, and a high proportion of respirable
droplets delivered in the shortest possible amount of time. Combined with
its silent mode of operation, small size (it fits in the palm of your
hand), light weight, and battery use, eFlow helps reduce the burden of
taking daily-inhaled treatments.
|SOURCE PARI Pharma|
Copyright©2007 PR Newswire.
All rights reserved